Videos

“Patients just need to be educated that you don't have to live this way,” says J. Welles Henderson, MD, FACOG.

"Given the time constraints and financial constraints of working in the systems that we all work within, trying to make it easier to get patients to these adjuvant services that do exist and making sure we capitalize and utilize those is critical," says Sarah P. Psutka, MD, MS.

“I think it's a very novel finding, and something completely new to urologic oncology, that a nonsurgical ablative option inside the body can actually make tumors go away,” says Sandip M. Prasad, MD, MPhil.

“I didn't want to only get coached; I thought, "Well, if I become a coach, maybe I can share this with others,” says Diana Londoño, MD.

"The one other thing that we think might be helpful is that for labs that are reporting free PSA results, the most value seems to be if you report from a PSA of 2 to 10," says Mark A. Preston, MD, MPH.

“For ATLAS, it was a different protocol. This was looking at giving the chemotherapy agent upfront,” says Sandip M. Prasad, MD, MPhil.

“[As] urologists and physicians, we should all appreciate AI's potential, but also understand its current limitations,” says Roei Golan.

"The goal here is obviously to identify men who need investigation and diagnosis of prostate cancer and who we don't need to biopsy at all," says Mark A. Preston, MD, MPH.

"It's the first randomized trial that I'm aware of in urine markers looking at standard of care versus a marker-based approach," says Yair Lotan, MD.

"One of the things that we want to look at long-term is how the kidney being exposed to limited durations of warm ischemia compared to no ischemia at all affects longitudinal atrophy," says Carlos Muñoz-Lopez.

A comprehensive discussion on clinical factors that impact pharmacologic treatment selection in patients with OAB.

Experts in urology share a brief conversation on recent and future legislation for insurance coverage and reimbursement, considering how it may impact their management of prostate cancer.

Panelists introduce the available treatment modalities for OAB, including behavioral modification, pharmacologic treatment, neuromodulation, and surgical approaches.

A more focused discussion on the specific challenges physicians or patients may face when seeking coverage or reimbursement for GnRH agonists/antagonists in prostate cancer.

“Listen to your body; these are the signals telling you something is out of balance,” says Diana Londoño, MD.

"Having a framework in place anticipating somebody may want to have a child in the program helps a lot," says Christine Van Horn, MD.

"We found that free PSA, when added to total PSA, improved prediction of clinically significant prostate cancer and fatal prostate cancer," says Mark A. Preston, MD, MPH.

Some patients with bladder cancer have been traveling to other regions for treatment if their location has no available cisplatin, explains Scott Tagawa MD.

“The primary thing we found was that the average kidney–and we study the ipsilateral kidney, or the kidney that was operated on–fell at the natural aging process,” says Carlos Muñoz-Lopez.

“It’s an exciting world in which we have all of these complications about what to do because it means we have a lot more choices for our patients,” said Scott Tagawa, MD.

"Some women are perceived as being less serious because they chose to build a family in training," says Christine Van Horn, MD.

“ChatGPT isn't yet ready to determine the quality of online text, but I think it's going to change in the future,” says Roei Golan.

Anna L. Myers, APRN-CNP, WHNP-BC, FNP-BC, IF, and Jean Marino, ARPN-CNP, NCMP, IF, preview an upcoming University Hospitals-led symposium titled, “What’s your pelvic floor plan? 2nd Annual Female Sexual Health Symposium.”

Yair Lotan, MD, explains how urine biomarker research needs to focus on how these markers can optimally fit into clinical algorithms for bladder cancer.

“I think this is a multidisciplinary approach,” says Monika Joshi, MD, MRCP.

“In many ways the field of urine markers is evolving but it has also hit some obstacles,” says Yair Lotan, MD.

"[These findings] will encourage us to continue to offer bladder neck incision to these patients if their bladder neck appears narrow after laser enucleation," says Nicholas S. Dean, MD.

“The more and more people we can get excited about this and collaborate with, the better results we're going to get and the more we're going to learn,” says Sunil H. Patel, MD, MA.

Centering discussion on insurance and reimbursement, key opinion leaders in prostate cancer management consider the current state of coverage for GnRH agonists/antagonists.

A brief review of the role that testosterone measurements play, amidst other monitoring strategies, in assessing for treatment failure in advanced prostate cancer.